ClinicalTrials.Veeva

Menu

Rivaroxaban Once Daily Versus Dose-adjusted Vitamin K Antagonist on the Biomarkers in Acute Decompensated Heart Failure and Atrial Fibrillation (ROAD HF-AF)

Yonsei University logo

Yonsei University

Status and phase

Unknown
Phase 4

Conditions

Acute Heart Failure

Treatments

Drug: Warfarin + LMWH
Drug: Rivaroxaban

Study type

Interventional

Funder types

Other

Identifiers

NCT03490994
4-2017-0776

Details and patient eligibility

About

Vitamin K antagonists (VKAs) are used to reduce the risk of stroke (cerebral vascular dysfunction) in AF patients. However, VKAs interact with drugs/food and the drug level is influenced by worsening of renal function, liver congestion or hemodynamic alterations in acute decompensated heart failure (ADHF). New oral anticoagulants (rivaroxaban, apixaban, dabigatran) are alternatives to VKA, such as warfarin. In post hoc analysis of ROCKET AF trial, 63.7% patients had HF and treatment-related outcomes were similar in patients with and without HF (Circulation HF. 2013; 6:740-7). So rivaroxaban 20 mg daily (or 15 mg daily in patients with creatinine clearance 30-49 mL/min) was safe in nonvalvular AF patients with HF. However, the clinical effect and safety of rivaroxaban were largely unknown in acute decompensated heart failure (ADHF) patients with atrial fibrillation (AF).

ROAD HF-AF is the exploratory study to assess the change of surrogate markers (hsTn, d-dimer) when treated with rivaroxaban vs. warfarin and to strengthen the basis for future biomarker-based therapy in ADHF patients

Enrollment

150 estimated patients

Sex

All

Ages

19+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:Hospitalized patients with a primary diagnosis of ADHF with AF One of the following criteria and LVEF ≤ 40% (at least 1 year before admission or admission)

  1. dyspnea at rest
  2. tachypnea; a respiratory rate > 20/min
  3. rales
  4. pulmonary edema on chest X-ray

Exclusion Criteria:

  1. History of increased bleeding risk (like ROCKET AF exclusion criteria)
  2. Contraindication to anti-coagulation therapy
  3. ACS diagnosis
  4. Hospitalization plan for PCI, coronary artery bypass graft surgery, other cardiac invasive interventions (e.g. catheter ablation, pacemaker, CRT, ICD implantation)
  5. Currently on dual anti-platelet therapy (aspirin + ADP receptor antagonist) or single antiplatelet therapy with a novel AP (e.g. Ticagrelor, Prasugrel)
  6. Cardiogenic shock (systolic blood pressure, SBP, < 80 mmHg)
  7. Patients with CrCl < 30 ml/min using creatinine-based CKD-EPI equations
  8. Elevated liver enzymes (3 times over upper reference limit) or liver cirrhosis
  9. Uncontrolled hypertension (SBP > 180 mmHg)
  10. Allergy, adverse drug reaction, hypersensitivity to rivaroxaban or warfarin
  11. Life expectancy < 6 months (e.g. metastatic malignancy)
  12. Pregnancy, or women of childbearing age

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

150 participants in 2 patient groups

Rivaroxaban
Experimental group
Description:
Rivaroxaban
Treatment:
Drug: Rivaroxaban
Warfarin
Active Comparator group
Description:
warfarin + enoxaparin
Treatment:
Drug: Warfarin + LMWH

Trial contacts and locations

1

Loading...

Central trial contact

Seok-Min Kang, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems